Switching clozapine dosing from twice daily to once daily for schizophrenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and tolerability of switching patients with schizophrenia from a twice-daily to a once-daily dosing regimen of clozapine. The study will be a pilot, double-blind, randomized controlled trial involving patients who have been on a stable twice-daily clozapine regimen for at least three months. By comparing the outcomes of the two dosing schedules, the trial seeks to determine if once-daily dosing is a viable alternative without compromising treatment effectiveness. The findings could provide insights into optimizing clozapine administration for better patient adherence and comfort.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with schizophrenia or schizoaffective disorder based on DSM-IV criteria
* Outpatient status
* Ages 18 years or older
* Has received clozapine twice a day, one of which is in the evening/bedtime, at the same dose and dosing regimen for at least 3 months
* Fluent in English and competent to provide written informed consent

Exclusion Criteria:

* Having significant medical or neurological illnesses
* Pregnant or lactating

Where it's running

• Centre for Addiction and Mental Health
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Gary Remington, MD, PhD — Centre for Addiction and Mental Health
• Study coordinator: Gary Remington, MD, PhD
• Email: Gary.Remington@camh.ca
• Phone: +1-416-535-8501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

• State Representation in Early Psychosis 2

  This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.

  Recruiting at 2 sites University of Minnesota · Minneapolis, Minnesota and 1 other locations · NCT07834203

• Trying the Kiso Mind smartphone app for people with schizophrenia spectrum disorders

  This study tests whether the Kiso Mind smartphone app is acceptable, practical, and helpful for adults with schizophrenia or schizoaffective disorder alongside their usual care.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07395206

• Valbenazine for adults with tardive dyskinesia who remain symptomatic on or after a VMAT2 inhibitor

  This trial will test whether valbenazine reduces involuntary movements in adults with tardive dyskinesia who still have symptoms while taking or after stopping a VMAT2 inhibitor.

  Recruiting at 19 sites Phase 4 Neurocrine Biosciences · Bryant, Arkansas and 18 other locations · NCT07105111

• Using AI to Improve Rehabilitation for Patients with Severe Mental Disorders

  This study is testing if using AI and fun games can help people with severe mental disorders improve their social skills and get back into the community.

  Recruiting Shanghai Mental Health Center · Shanghai · NCT06904079

• Enhancing Veteran-Clinician Collaboration in VA Care for Serious Mental Illness

  This study tests a 10-session group program to help Veterans with serious mental illness collaborate better with their clinicians and care teams.

  Recruiting VA Office of Research and Development · San Diego, California and 2 other locations · NCT06898879

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.